PEMAZYRE dosing and administration — 3 of 5

PEMAZYRE allows simple dose modifications

Tablets are available in 3 strengths (13.5 mg, 9 mg and 4.5 mg) to enable dose modification as needed1

Recommended dose reductions1

Recommended dose

13.5 mg

taken orally once daily for 14 days on, followed by 7 days off therapy

First dose reduction

9 mg

taken orally once daily for 14 days on, followed by 7 days off therapy

Second dose reduction

4.5 mg

taken orally once daily for 14 days on, followed by 7 days off therapy

Permanently discontinue if unable to tolerate PEMAZYRE 4.5 mg once daily1

Adapted from reference 1.


For further information, please refer to the PEMAZYRE Summary of Product Characteristics.1

  • Dose modifications or interruption of dosing should be considered for the management of toxicities1
  • Where possible, concurrent use of strong CYP3A4 inhibitors (eg, itraconazole, ketoconazole, ritonavir) should be avoided during treatment with PEMAZYRE1
    • If co-administration with a strong CYP3A4 inhibitor is necessary, the dose of patients who are taking 13.5 mg PEMAZYRE once daily should be reduced to 9 mg once daily and the dose of patients who are taking 9 mg PEMAZYRE once daily should be reduced to 4.5 mg once daily1
Question mark icon

Special populations

Question mark icon

Interaction with other medicinal products and other forms of interaction